3 New Strong Buy Ratings from Top-Rated Analysts: 10/14/2025

Got gaps in your portfolio? Consider these high-conviction picks from our Strong Buy Stocks from Top Wall Street Analysts screener:

• BeOne Medicines (ONC) demonstrates solid growth
• Past Stock of the Week pick pick Jones Lang Lasalle (JLL) is back on our radar
• MasTec (MTZ) is killing it right now — here’s why Strong Buy alerts are flashing 

P.S. Get more alerts like this daily … Try WallStreetZen Premium.

A note from our sponsors...

1. BeOne Medicines (NASDAQ: ONC) 

BeOne Medicines is an oncology-focused biotech business that has demonstrated solid EPS growth thus far in 2025. ONC has rallied by 73.97% since the start of the year, and one of Wall Street’s finest analysts believes there’s still double-digit upside in the cards — to further sweeten the pot, the stock has dipped by almost 7% in the past week, so it’s currently trading at a discount.

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $320.10 — get current quote > 

Max 1-year forecast: $385.00 

Why we’re watching:

• BeOne Medicines is covered by 7 Wall Street analysts — their coverage is split between 5 Strong Buy ratings and 2 Buy ratings. See the ratings 
• The average 12-month price forecast for ONC shares, currently pegged at $353.43, implies a healthy 10.41% upside.
• JP Morgan researcher Jessica Fye (a top 4% rated analyst) recently maintained a Strong Buy rating on the stock and increased her price target from $345 to a Street-high $385.
• Fye contextualized their price target hike on BeOne Medicines by arguing that its "broad" oncology pipeline supports "durable" growth.
• Looking ahead, the analyst detailed that "two value-inflecting pivotal data readouts for BeOne Medicines as visible, data for its BTK inhibitor in first-line mantle cell lymphoma in 2H 2025, and data in first-line gastroesophageal cancer for its PD1 inhibitor, anti-HER2 combination in Q4."
• Our quant rating system, Zen Ratings, evaluates stocks on the basis of 115 proprietary factors. The equities that rank in the top 5% are given a Zen Rating of A — and have provided an average annual return of 32.52% since the early 2000s. At present, ONC ranks in the top 4% of the stocks that we track.
• Each Zen Rating is a composite score made up from 7 Component Grade ratings. So, for instance, ONC ranks in the top 18% in terms of Momentum, and the top 16% when it comes to Value.
• BeOne Medicines shares also rank in the top 6% with regard to Artificial Intelligence. This means that a neural network trained on more than two decades of market data has identified the stock as a likely outperformer.
• Lastly, we have the star of the show — Growth. Here, ONC ranks in the 99th percentile of the stocks that we track. (See all 7 Zen Component Grades here >)

2. Jones Lang Lasalle (NYSE: JLL)

Real estate markets tend to ebb and flow — but Jones Lang Lasalle has been in business since 1997, and has managed to both weather crises and thrive when conditions are favorable. This past Stock of the Week pick has been named one of the most admired companies in the world by Fortune magazine. Five consecutive earnings beats have proven that this real estate business has kept up with the times — and we have reason to believe it will continue to outperform.

Zen Rating: B (Buy) — see full analysis >  

Recent Price: $283.23 — get current quote > 

Max 1-year forecast: $378.00 

Why we’re watching:

• JLL shares have 3 Strong Buy ratings, 1 Buy rating, and 1 Hold rating. See the ratings  
• The average 12-month price forecast for Jones Lang Lasalle stock is currently pegged at $339, and implies a hefty 19.69% upside.
• UBS equity researcher Alex Kramm (a top 12% rated analyst) maintained a Strong Buy rating on the stock ahead of the company’s Q3 2025 earnings report, due November 5. Kramm also increased his price target from $340 to $370.
• In a U.S. Real Estate Brokers sector quarterly preview note, Kramm told readers to expect results showing that recovery is continuing at a moderating pace.
• Jones Lang Lasalle shares rank in the top 9% of the equities that we track, giving them a Zen Rating of B, which has historically corresponded to an average annual return of 19.88%.
• JLL ranks in the top 25% in terms of Value, as the stock is currently trading at a very attractive price to earnings (P/E) ratio of 23.86x and a price to earnings growth (PEG) ratio of 0.9xx.
• Our Sentiment Component Grade rating takes into account factors such as earnings surprises, short interest, earnings revisions, and insider buying or selling. In this category, Jones Lang Lasalle ranks in the 77th percentile.
• Safety is another high point here — when it comes to this Component Grade rating, the stock ranks in the top 22%.
• However, the company’s balance sheet is its strongest suit — with regard to Financials, JLL ranks in the 89th percentile of the equities that we track. (See all 7 Zen Component Grades here >)

3. MasTec (NYSE: MTZ) 

MasTec is an infrastructure construction business — but there’s an important twist. The business specializes in electrical transmission networks, 5G deployment, and renewable energy infrastructure. More recently, it has also expanded into data centers. Per a recent earnings report, our latest pick also has a record-breaking $15.9 billion backlog. However, it is the MTZ’s growth potential going forward that makes it worth a closer look.  

Zen Rating: A (Strong Buy) — see full analysis >  

Recent Price: $203.88 — get current quote > 

Max 1-year forecast: $290.00 

Why we’re watching:

• MasTec enjoys broad, bullish coverage from Wall Street equity researchers. The stock currently has 15 Strong Buy ratings and 2 Buy ratings. See the ratings 
• The average price target for MTZ is currently pegged at $225.94, and implies a hefty 15.51% upside.
• Brian Brophy of Stifel Nicolaus (a top 7% rated analyst) recently maintained a Strong Buy rating on MasTec, and increased his price target from $198 to $237.
• Brophy's update on Mastec followed Stifel Nicolaus' channel checks on names in its Industrials and Materials sector coverage area.
• Among the key findings from the survey, according to the analyst, were the fact that transmission and distribution equipment and services activity increased significantly and beyond expectations in Q3, and that bidding and awards witnessed "notable improvement.
• Based on the survey results, Brophy said the group's T&D-related businesses are in a good position going into the prints.
• Truist Securities researcher Jamie Cook (also a top 7% rated analyst) also maintained a Strong Buy rating, and upped his price target from $209 to $248.
• In a quarterly preview of names in their Machinery, Infrastructure Services, and Multi-Industry Industrial Technology portfolio, Cook told readers to expect modest beats and raises for the Engineering and Construction group because of robust backlogs
• MTZ is the 9th highest-rated stock in the Engineering & Construction industry, which has an Industry Rating of A.
• MasTec shares rank in the top 5% of the equities that we track, giving it a Zen Rating of A.
• MTZ has rallied by 39.72% since the start of the year, and ranks in the top 12% when it comes to Momentum. The stock also ranks in the top 11% in terms of Safety.
• MasTec’s Sentiment Component Grade rating is another highlight — here, it ranks in the 90th percentile.
• Lastly, we have Growth — a category in which MTZ shares rank in the top 1% of the equities that we track. (See all 7 Zen Component Grades here >)

What to Do Next?

• 77 Best Stocks NOW! >
• See All “A” Rated Stocks with +32.52% Average Annual Return >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.